CompanyNYSEOr Akiva

Regentis Biomaterials LTD

Regentis Biomaterials develops Gelrin, a degradable hydrogel platform for tissue regeneration.

SEC EDGAR ClinicalTrials.gov

6-KNov 9Latest SEC filing

Form DJun 25$6.5M sold

October 2026

Regentis reports surgeon interest in GelrinC at ICRS Summit in Portugal

Oct 13Regulatory decisionRegentis Biomaterials LTD